07:40 AM EDT, 10/07/2024 (MT Newswires) -- Scholar Rock Holding ( SRRK ) said Monday a phase 3 trial for its investigational therapy apitegromab met its primary endpoint.

Patients with spinal muscular atrophy showed 'statistically significant and clinically meaningful improvement' in motor function after receiving apitegromab, Scholar Rock ( SRRK ) said.

The company said it plans to submit a Biologics License Application in the US and a marketing authorization application in the EU for the treatment in Q1.

Price: 28.03, Change: +20.61, Percent Change: +277.76